JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of phase I clinical study of JWATM204 in patients with advanced hepatocellular carcinoma (HCC). Primary liver cancer (PLC), also known as liver carcinoma, is one of the common gastrointestinal malignancies worldwide. Approximately...
Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders
LACHEN, Switzerland, July 4, 2022 /PRNewswire/ -- Octapharma to present new clinical and scientific data from across Octapharma's haematology and critical care portfolios during the ISTH 2022 Congress Data to be presented in 11 poster presentations and during two Supported Symposia New data from the extensive clinical trial programme with Nuwiq®...
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061
SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, referred to "Abbisko Therapeutics" hereafter) today announced completion of dosing of the first patient in the Phase 1 clinical trial in advanced solid tumors for ABSK061, which becomes the first highly selective FGFR2/3 inhibitor advanced into clinical stage globally. The clinical trial...
Investing in people to reach their full potential – An impactful part of one CEO’s journey towards creating a sustainable world
PETALING JAYA, Malaysia, July 4, 2022 /PRNewswire/ -- In a book aptly named "The Book of Wisdom" recently published by the Entrepreneurs Organization (EO) of Malaysia, Mr. Lim Boon Siong, CEO of VISTA Eye Specialist was asked for words of wisdom to share with readers, to which he replied "When you like a flower, you just pluck it. But...
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the clinical study of PD-L1 antibody ASC22 in combination with Chidamide for functional cure of human immunodeficiency virus (HIV) infection, which was initiated by Shanghai Public Health Clinical Center, has completed the first patient dosing recently. Previously, Ascletis announced the...
Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis
SAN FRANCISCO and SUZHOU, China, July 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, announced that the first patient with moderate-to-severe active ulcerative colitis has been successfully dosed in a Phase 2 clinical study...
Brii Biosciences Exercises Option for Vir Biotechnology’s VIR-3434, a Broadly Neutralizing Monoclonal Antibody Targeting Hepatitis B in Greater China
Exclusive development and commercialization rights to VIR-3434 in China strengthen Company's leadership and robust clinical pipeline in HBV Key partnership with Vir enables multitude of combination treatment options as part of Company's strategic approach to developing a functional cure for HBV DURHAM, N.C. and BEIJING, July 4, 2022 /PRNewswire/ -- Brii Biosciences...
Chubb Life Announces Gail Costa Will Lead Newly Acquired Life Insurance Operations of Cigna in New Zealand
HONG KONG, July 4, 2022 /PRNewswire/ -- Chubb Life today announced that Gail Costa will lead the company's life insurance operations in New Zealand that were recently acquired from Cigna. Ms. Costa, who is currently Chief Executive Officer of Cigna Life New Zealand, will continue to have executive operating responsibility for the business, which will...
ReviR Therapeutics Appoints Paul August, Ph.D., as Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., July 1, 2022 /PRNewswire/ -- ReviR Therapeutics, a biotechnology company focused on developing RNA-targeting small molecule drugs, announced the appointment of Paul August, Ph.D., as the Chief Scientific Officer. "We are thrilled to welcome Dr. August to our team," said Peng Yue, Ph.D., Co-Founder, and Chief Executive Officer of ReviR Therapeutics. "Paul has extensive experience in...
IMG Partners with eMed to Provide Telehealth Proctored COVID-19 Tests to Groups of International Travelers
INDIANAPOLIS, July 1, 2022 /PRNewswire/ -- International Medical Group® (IMG®), an award-winning global insurance benefits and assistance services company, has announced a new partnership with eMed, the architect behind the first virtually guided, rapid at-home COVID-19 certified test technology and platform. IMG is excited to offer eMed's at-home COVID-19 tests in bulk...
